Connection

Bikash Medhi to Humans

Back to Details
This is a "connection" page, showing publications Bikash Medhi has written about Humans.
Bikash Medhi
Connection Strength
0.303
Humans
  1. Update on geographical variation and distribution of SARS-nCoV-2: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):310-316.
    View in: PubMed
    Score: 0.008
  2. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jul-Aug; 53(4):317-327.
    View in: PubMed
    Score: 0.008
  3. nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis. Sci Rep. 2021 06 18; 11(1):12888.
    View in: PubMed
    Score: 0.008
  4. Promising traditional Indian medicinal plants for the management of novel Coronavirus disease: A systematic review. Phytother Res. 2021 Aug; 35(8):4456-4484.
    View in: PubMed
    Score: 0.008
  5. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review. Eur J Pharmacol. 2021 Sep 05; 906:174233.
    View in: PubMed
    Score: 0.008
  6. Structural and conformational analysis of SARS CoV 2 N-CTD revealing monomeric and dimeric active sites during the RNA-binding and stabilization: Insights towards potential inhibitors for N-CTD. Comput Biol Med. 2021 07; 134:104495.
    View in: PubMed
    Score: 0.008
  7. Antimicrobial resistance: An unseen threat prowling behind the COVID-19 outbreak. Indian J Pharmacol. 2021 May-Jun; 53(3):187-191.
    View in: PubMed
    Score: 0.008
  8. Efficacy and safety of inhaled nitric oxide in the treatment of severe/critical COVID-19 patients: A systematic review. Indian J Pharmacol. 2021 May-Jun; 53(3):236-243.
    View in: PubMed
    Score: 0.008
  9. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Ann Intern Med. 2021 03; 174(3):434.
    View in: PubMed
    Score: 0.007
  10. Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable? Med Hypotheses. 2021 Apr; 149:110539.
    View in: PubMed
    Score: 0.007
  11. Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review. Biomed Pharmacother. 2021 May; 137:111300.
    View in: PubMed
    Score: 0.007
  12. Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review. Tissue Cell. 2021 Jun; 70:101497.
    View in: PubMed
    Score: 0.007
  13. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep. 2021 Jun; 73(3):736-749.
    View in: PubMed
    Score: 0.007
  14. Indian contribution toward biomedical research and development in COVID-19: A systematic review. Indian J Pharmacol. 2021 Jan-Feb; 53(1):63-72.
    View in: PubMed
    Score: 0.007
  15. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. Int J Antimicrob Agents. 2020 Dec; 56(6):106224.
    View in: PubMed
    Score: 0.007
  16. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis. Indian J Pharmacol. 2020 Nov-Dec; 52(6):535-550.
    View in: PubMed
    Score: 0.007
  17. Human animal interface of SARS-CoV-2 (COVID-19) transmission: a critical appraisal of scientific evidence. Vet Res Commun. 2020 Nov; 44(3-4):119-130.
    View in: PubMed
    Score: 0.007
  18. Novel therapeutic approaches toward Hantaan virus and its clinical features' similarity with COVID-19. Indian J Pharmacol. 2020 Sep-Oct; 52(5):347-355.
    View in: PubMed
    Score: 0.007
  19. Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients. Indian J Pharmacol. 2020 Sep-Oct; 52(5):414-421.
    View in: PubMed
    Score: 0.007
  20. Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. Life Sci. 2020 Oct 01; 258:118207.
    View in: PubMed
    Score: 0.007
  21. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic? Allergol Immunopathol (Madr). 2020 Sep - Oct; 48(5):507-517.
    View in: PubMed
    Score: 0.007
  22. Pattern of clinical research in the era of COVID-19 pandemic: A new learning experience for the present as well as future. Indian J Pharmacol. 2020 Jul-Aug; 52(4):249-253.
    View in: PubMed
    Score: 0.007
  23. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020 Jul-Aug; 52(4):313-323.
    View in: PubMed
    Score: 0.007
  24. Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. Indian J Pharmacol. 2020 Mar-Apr; 52(2):75-78.
    View in: PubMed
    Score: 0.007
  25. COVID-19 pandemic: A review based on current evidence. Indian J Pharmacol. 2020 Mar-Apr; 52(2):117-129.
    View in: PubMed
    Score: 0.007
  26. Update on the target structures of SARS-CoV-2: A systematic review. Indian J Pharmacol. 2020 Mar-Apr; 52(2):142-149.
    View in: PubMed
    Score: 0.007
  27. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain). J Biomol Struct Dyn. 2021 05; 39(8):2724-2732.
    View in: PubMed
    Score: 0.007
  28. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol. 2020 07; 92(7):776-785.
    View in: PubMed
    Score: 0.007
  29. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach. Indian J Pharmacol. 2020 Jan-Feb; 52(1):1-5.
    View in: PubMed
    Score: 0.007
  30. Drug targets for corona virus: A systematic review. Indian J Pharmacol. 2020 Jan-Feb; 52(1):56-65.
    View in: PubMed
    Score: 0.007
  31. Developing and sustaining India's capacity for preclinical drug discovery. Indian J Pharmacol. 2018 Sep-Oct; 50(5):225-226.
    View in: PubMed
    Score: 0.006
  32. Modulation of endocannabinoid system: Success lies in the failures. Indian J Pharmacol. 2018 Jul-Aug; 50(4):155-158.
    View in: PubMed
    Score: 0.006
  33. Cefixime-associated acute generalized exanthematous pustulosis: Rare cases in India. Indian J Pharmacol. 2018 Jul-Aug; 50(4):204-207.
    View in: PubMed
    Score: 0.006
  34. Cracking novel shared targets between epilepsy and Alzheimer's disease: need of the hour. Rev Neurosci. 2018 Jun 27; 29(4):425-442.
    View in: PubMed
    Score: 0.006
  35. mHealth technologies in clinical trials: Opportunities and challenges. Indian J Pharmacol. 2018 May-Jun; 50(3):105-107.
    View in: PubMed
    Score: 0.006
  36. Old wines in new bottles: Repurposing opportunities for Parkinson's disease. Eur J Pharmacol. 2018 Jul 05; 830:115-127.
    View in: PubMed
    Score: 0.006
  37. Understanding the controversial drug targets in epilepsy and pharmacoresistant epilepsy. Rev Neurosci. 2018 Mar 28; 29(3):333-345.
    View in: PubMed
    Score: 0.006
  38. Specifically targeted antimicrobial peptides: A new and promising avenue in selective antimicrobial therapy. Indian J Pharmacol. 2018 Jan-Feb; 50(1):1-3.
    View in: PubMed
    Score: 0.006
  39. Cosmetovigilance in India: Need of the day. Indian J Pharmacol. 2017 Sep-Oct; 49(5):341-343.
    View in: PubMed
    Score: 0.006
  40. Orphan drugs: Indian perspective. Indian J Pharmacol. 2017 Jul-Aug; 49(4):267-269.
    View in: PubMed
    Score: 0.006
  41. Experience of an academic institute in importing a novel preclinical drug into India. Indian J Pharmacol. 2017 Jul-Aug; 49(4):322-324.
    View in: PubMed
    Score: 0.006
  42. Use of Bacteria in Cancer Therapy. Recent Results Cancer Res. 2016; 209:111-121.
    View in: PubMed
    Score: 0.005
  43. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis. Indian J Med Res. 2021 Jan & Feb; 153(1 & 2):219-226.
    View in: PubMed
    Score: 0.002
  44. Naltrexone a potential therapeutic candidate for COVID-19. J Biomol Struct Dyn. 2022 02; 40(3):963-970.
    View in: PubMed
    Score: 0.002
  45. Letter to the editor: Possible role of topical povidone iodine in case of accidental ocular exposure to SARS-CoV-2. Graefes Arch Clin Exp Ophthalmol. 2020 11; 258(11):2575-2578.
    View in: PubMed
    Score: 0.002
  46. Possible prophylactic or preventive role of topical povidone iodine during accidental ocular exposure to 2019-nCoV. Graefes Arch Clin Exp Ophthalmol. 2020 11; 258(11):2563-2565.
    View in: PubMed
    Score: 0.002
  47. A New Therapeutic Approach for Brain Delivery of Epigallocatechin Gallate: Development and Characterization Studies. Curr Drug Deliv. 2019; 16(1):59-65.
    View in: PubMed
    Score: 0.002
  48. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol. 2019 Feb 05; 844:231-240.
    View in: PubMed
    Score: 0.002
  49. An intervention to evaluate & improve handling of cancer drugs in a tertiary care hospital in India. Indian J Med Res. 2017 08; 146(2):285-287.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.